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III clinical trials. In this review we will argue that wrong timing of 
drug administration, incomplete knowledge, and biased assump-
tions about of the role of neuroinflammation in neurodegeneration 
may have led to the current impasse. Revision of anti-inflammatory 
treatments in the light of the dynamic model of AD progression 
will thus provide new research and clinical directions.
EpidEmiological data and clinical trials
The epidemiological studies and clinical trials that, in striking number 
– over 40 –, have been developed to examine the benefits of NSAID 
in AD have been thoroughly described elsewhere (Imbimbo et al., 
2010). The results are paradoxical: while the epidemiological data 
points to a reduced incidence of AD in NSAID users, most of the 
ensuing clinical trials in AD or mild cognitive impairment (MCI) 
have shown no effect or even detrimental effects. These results have 
casted serious doubts on epidemiological analyses and, therefore, on 
NSAID-based therapeutics for AD after the initial hype in the 90s. 
In hindsight, among the several explanations put forth to explain 
the discrepancy between epidemiological data and clinical trials – 
including wrong choice of NSAID or dosage in clinical trials, recall 
bias in epidemiological studies, or that arthritis, not NSAIDs, is the 
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A group of leading Alzheimer’s disease (AD) experts have recently 
integrated available information about the five best characterized 
biomarkers into a dynamic model of disease evolution overtime 
(Jack et al., 2010). This groundbreaking contribution provides a 
framework to select individuals for clinical trials, and decide upon 
outcome measurements. According to the model, AD progresses in 
a continuum where stages can be defined by biomarkers. There is a 
damaging phase wherein amyloid β(Aβ) and hyperphosphorylated 
tau accumulate (phase 1), followed by a phase of synaptic and meta-
bolic alterations (phase 2), which leads to a final stage when clinical 
symptoms – cognitive impairment and brain atrophy – are detected 
(phase 3). This model fairly recapitulates the emerging view that 
there is a clinically silent phase in AD that can last up 20 years before 
dementia is manifest. Henceforth, any therapy for AD will need to 
be contrasted with this paradigm. This is the case of non-steroidal 
anti-inflammatory drugs (NSAIDs). The field of neuroinflamma-
tion in AD has taken several unexpected turns from the Rotterdam 
epidemiological study reporting, in 2001, a 80% decrease in the risk 
of developing AD in long-term users of NSAIDs, to the ensuing 
failure of some NSAIDs and derivatives like R-flurbiprofen in phase 
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protective factor – a research group in Baltimore may have got it 
right. They argued that, since protection was only observed after 
sustained uptake well before the onset of AD, NSAIDs were preven-
tive and would not work in clinical trials with patients. To test this 
idea, they launched in 2000 a primary prevention trial, the ADAPT 
trial, to test the effect of naproxen (a dual cycloxygenase type 1, COX1 
and 2, COX2 inhibitor) and celecoxib (a selective COX2 inhibitor) 
in healthy volunteers, 70-years-old in average. Unfortunately, the 
ADAPT trial was cancelled after 2 years and a half over concerns of 
cardiovascular damage by COX2 inhibitors, although the group have 
kept reporting the progression of AD incidence overtime. At the time 
of cancellation, no protection was observed by NSAID, and even the 
cohort taking naproxen appeared to fare worse than the placebo 
group. However, 2 years later (i.e., 4 years after the start of the treat-
ment) the data indicated (70% protection in naproxen users (Hayden 
et al., 2007). That is, naproxen conferred protection to people in the 
path to have dementia if they were at least 4 years shy of developing 
clinical signs. The evidence supports that NSAIDs need to be taken 
during preclinical phases of AD, and would validate the conclusions 
of epidemiological data. It is worth stressing that numerous clinical 
trials for AD with purported disease-modifying drugs have spectacu-
larly failed in the last years (Sabbagh, 2009). These sobering results 
have prompted the view that disease- modifying drugs, including 
NSAIDs, will be efficacious only if administered preventively before 
neurodegeneration is well advanced. According to a meta-analysis 
of epidemiological data (Szekely et al., 2004), NSAIDs reduce AD 
incidence by an average of 58%. If this figure is translated into patient 
numbers, anti-inflammatory treatment arises as a worth pursuing 
strategy to significantly reduce the socio- economical burden caused 
by AD. But first, a complete prevention trial is necessary. The ADAPT 
trial illustrates the difficulties of primary prevention trial design, 
including selecting individuals on their way toward AD, tracking 
disease progression, and deciding upon most efficient treatment 
drugs and protocols. Considering that the average onset of AD is 
65- to 70-years-old, and that NSAIDs work only if taken 4 years 
before the disease is clinically detected, participants in the prevention 
trial should be 60- to 65-years-old. Are currently available cognitive, 
neuroimaging, and blood tests valid to include individuals in the 
trial, and to measure outcomes? The experience accumulated by the 
Alzheimer’s Disease Cooperative Study (ADCS) dictates that Aβ42 
contents in cerebrospinal fluid (CSF) can be used for subject selec-
tion ((193 pg/ml, cut-off value), while fluorodeoxyglucose (FDG) 
contents and hippocampal volume are appropriate surrogate markers 
for disease progression (Aisen, 2010; Jack et al., 2010). The former can 
be traced by positron emission tomography (PET), while the latter 
is routinely assessed with magnetic resonance (MRI). Importantly, 
participants should carry the allele ε4 of apolipoprotein E (ApoEε4) 
because, according to epidemiological data, NSAIDs are effective only 
in this subpopulation (In’t Veld et al., 2001; Yip et al., 2005; Hayden 
et al., 2007; Szekely et al., 2008), which brings up the next question 
about the target of NSAIDs.
molEcular, cEllular, and functional targEts  
of nsaids
The quest for the underpinnings of NSAID-mediated protec-
tion is confounded by two factors. One, the realization that AD 
progresses in stages implies that NSAID actions may differ with 
the stage of disease progression. Two, NSAIDs may be multifunc-
tional drugs targeting non-inflammatory molecules aside from 
cyclooxygenases (COXs).
In the model of AD progression, asymptomatic phases 1 and 2 
are the target zones for preventive therapy (Figure 1), and presum-
ably where NSAIDs are acting upon according to epidemiological 
data. Decreased CSF-Aβ42 defines phase 1, while increased CSF-
tau, decreased PET-FDG, and decrease of hippocampal volume are 
signs of neuronal injury and dysfunction in phase 2 (Jack et al., 
2010). The “inflammation” associated to these preclinical phases is 
not well characterized. In general, “neuroinflammation” has grown 
to be a too wide term encompassing a body of standard reactions 
against tissue damage or infection, with little consideration for 
specifics of disease, stage of disease progression, brain area, or 
cell type. In AD, researchers have mostly relied on post-mortem 
brains from demented patients, plaque-laden transgenic models, 
or cell cultures. The use of these materials has imposed a biased 
view of inflammation in AD pathogenesis, based on observations 
pertaining phase 3, which place microglia-derived neurotoxins as 
culprit of the disease (see below). A single study illustrates this 
misconception. Jacobsen et al. (2006) have reported dendrite dam-
age, memory deficits and behavioral alterations in a transgenic-
mouse model of AD months before Aβ plaques appear. Glial cells, 
the holders of the innate immune system, could not account for 
this early damage because reactive astrocytes and microglia were 
visible later, in parallel with plaque deposition. Whether a subtle 
earlier glia response went unnoticed, or if a second wave of dam-
age followed the plaque-associated canonical inflammation was 
not determined. In order to understand the modus operandi of 
NSAIDs it is necessary to: (i) define stages 1–3 in animal models, 
and (ii) focus on asymptomatic or early stages in disease progres-
sion in mice and humans. Specifically, we have to clarify the role 
of glial cells on: (i) mitochondrial damage, production of reactive 
oxygen species (ROS), and oxidative lesions to proteins or nucleic 
acids, (ii) metabolic impairment, as defined by PET-FDG, and (iii) 
decreases in hippocampal volume, all preclinical or early signs of 
damage in humans (Fox et al., 1999; Nunomura et al., 2001; Petrie 
et al., 2009; Martinez et al., 2010). In AD transgenic mice, oxidative 
damage to lipids occurs before Aβ deposition (Pratico et al., 2001), 
and an interplay exists between Aβ production and oxidative dam-
age (Tamagno et al., 2002; Lustbader et al., 2004). Whether glial 
cells reinforce or attenuate these cascades, and if astrocytes and 
microglia have different roles, remain unknown.
The possible multifunctional nature of NSAIDs is supported by 
cumulative evidence showing that the drugs, other than COX, can 
target γ-secretase (Weggen et al., 2003), Rho-GTPases (Fu et al., 
2007), and peroxisome proliferator-activated receptors (PPAR) 
(Nicolakakis et al., 2008). The γ-secretase mediates production of 
Aβ, while Rho-GTPases regulate several phenomena relevant to 
AD including axon growth (Fu et al., 2007), tau phosphorylation 
(Sayas et al., 1999), and astrocyte motility (Lichtenstein et al., 2010). 
Finally, PPARs are powerful modulators of inflammation (Pascual 
et al., 2005), oxidative stress (Nunomura et al., 2001; Kang et al., 
2005), and Aβ production via BACE (Sastre et al., 2006).
The real molecular target of NSAIDs has been arguably the 
most elusive question in anti-inflammatory therapeutics in AD. 
In the early 90s it was thought that NSAIDs prevented via COX2 
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the  detrimental effects of chronic microglia activation. The  failure 
of  clinical trials with COX2 inhibitors and corticosteroids, together 
with the fortuitous finding that some NSAIDs modulated γ-secretase, 
thereby decreasing the production of Aβ42, prompted researchers 
and companies to modify the chemical structure of NSAIDs to 
increase specificity and potency toward γ-secretase. R-flurbiprofen 
was born (Kukar et al., 2007) but failed in Phase III clinical trial 
(Green et al., 2009), probably because, as we believe now, disease-
modifying drugs are only effective pre-clinically. Of note, naproxen 
is not a γ-secretase modulator (Takahashi et al., 2003), suggest-
ing that the protective effects revealed by the recent ADAPT trial 
follow-up are γ-secretase-independent. Whether NSAIDs act on 
PPAR receptors and/or Rho-GTPases in vivo is unknown, but it 
is desirable that they did, in view of the large number of possible 
beneficial actions (Table 1). Efforts to streamline NSAID specificity 
may thus render therapeutically weaker drugs, and should await 
further characterization of NSAID targets. Finally, COX1 should 
be redeemed back for now as a possible target in view of recent 
evidence indicating robust protective effects of triflusal in a AD 
mouse model (Choi et al., 2009; Coma et al., 2010).
thE rolE of apoEξ4
The startling conclusion from the epidemiological data that NSAIDs 
are protective exclusively in ApoEε4 carriers (In’t Veld et al., 2001; 
Yip et al., 2005; Hayden et al., 2007; Szekely et al., 2008) places the 
lipoprotein as a possible target of NSAIDs. Although inheritance of 
ApoEε4 allele is the strongest known risk factor for the development 
of sporadic AD (Ertekin-Taner, 2010), the mechanisms underlying 
this correlation are not well understood. ApoEε4 carriers actually 
experience memory loss beginning in their fifties (Caselli et al., 
2009), strongly indicating that ApoEε4-related damage is an early 
event in disease progression. ApoE controls cholesterol homeosta-
sis. Most of the evidence indicates that ApoE promotes the clearance 
and/or degradation of Aβ via the physical interaction between the 
two proteins, and that ApoEε4 performs this function worse than 
ApoEε3 or ApoEε2 (Kim et al., 2009), thereby contributing to Aβ 
accumulation in the brain. Moreover, ApoE is immunomodulatory 
(Pocivavsek et al., 2009), and the allele matters: ApoEε4 is associ-
ated to greater production of pro-inflammatory cytokines than 
ApoEε3 in mice challenged with lipopolysaccharide (Vitek et al., 
2009). This indicates that apoEε4 protein may alter inflammation 
partly by dose effects (i.e., a net decrease in ApoE production), and 
partly by being qualitatively different than ApoEε3.
FigurE 1 | integration of NSAiD actions in the dynamic model of AD 
evolution. Adapted from Jack et al. (2010). Dysfunctional astrocytes would exert 
a primary role in early disease events by promoting Aβ accumulation, and by 
affecting neurovascular coupling, metabolic homeostasis, or synaptic plasticity. 
Microglia activation would be secondary to Aβ accumulation and neuronal 
damage. NSAID effects would depend on the stage of disease progression. 
Initially, the drugs would be beneficial by counteracting ApoEε4-mediated 
detrimental effects, whereas in advanced stages NSAID may offer no protection, 
or become detrimental by further blocking faulty microglia/myeloid cell attempts 
at Aβ clearance and tissue repair.
Table 1 | Possible targets of NSAiDs.
Molecular target Functional target references
PPAR Inflammation (via NFkB) Pascual et al. (2005)
 Oxidative stress Nunomura et al. (2001), 
  Kang et al. (2005)
 Apoptosis Fuenzalida et al. (2007)
 Cerebrovascular protection Nicolakakis et al. (2008)
 BACE Sastre et al. (2006)
Rho-GTPases Axon growth Fu et al. (2007)
 Tau phosphorylation Sayas et al. (1999)
 Astrocyte motility Lichtenstein et al. (2010)
COX Microglia modulation Choi et al. (2009)
ApoE Astrocyte dysfunction Zhong et al. (2009)
γ-Secretase Reduction of Ab42 Weggen et al. (2003)
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reports that chronic overexpression of IL-1( in the hippocampus 
of APP/PS1 transgenic animals results in decreased plaque burden 
and insoluble Aβ peptide, with no alterations in A( processing or 
APP expression (Shaftel et al., 2007). The increased number of 
peri-plaque microglia points to increased Aβ phagocytosis as the 
underlying mechanism, consistent with the observation that micro-
glia expresses phagocytic markers (Jimenez et al., 2008). Thus, there 
is a basis to support that microglia are phagocytes, but the following 
points have to be made.
(i) Resident microglia has little phagocytic capacity toward Aβ 
according to animal models (Simard et al., 2006; Majumdar 
et al., 2008; Grathwohl et al., 2009). The phagocytic potential 
can be enhanced or restored with inflammatory agents such 
as IL-1β (Shaftel et al., 2007), lipopolysaccharide (Herber 
et al., 2004), or granulocyte colony stimulating factor (G-CSF) 
(Sanchez-Ramos et al., 2009). That is, “classic” inflammation 
activates the “alternative” phenotype. It follows that inhibition 
of the former may cause inhibition of the latter. A proportion 
of brain phagocytes are blood or bone-marrow derived mono-
cytes, which infiltrate the brain and cluster around Aβ plaques 
(Malm et al., 2005; Simard et al., 2006; Butovsky et al., 2007; 
Town et al., 2008). Interestingly, monocyte recruitment depends 
on the chemoattractant MCP-1 (El et al., 2007), pointing to a 
cross-talk between cerebral and peripheral immune systems.
(ii) Ultrastructural analysis of post-mortem brains from AD 
patients reveals no sign of Aβ fibers in the lysosomal system of 
peri-plaque microglia (Wisniewski et al., 1992), despite the fact 
that they express the phagocyte marker human leukocyte anti-
gen type DR (HLA-DR) (McGeer et al., 1987). This suggests 
defective activation. Currently, researchers are pursuing various 
means to activate Aβ phagocytosis in brain by resident or infil-
trated cells. Strategies include immunotherapy (Schenk et al., 
2004), or infusion of Aβ-specific T-cells (Ethell et al., 2006).
(iii) Microglia or myeloid cells can also contribute to Aβ removal 
through the release of proteolytic enzymes (Jiang et al., 2008), 
or the component system element C3 (Wyss-Coray et al., 
2002). Activation of the complement system would thus have 
a protective rather than the allegedly detrimental role in AD.
Overall, it appears that the inflammatory activation of microglia 
detected in clinical stages of AD, or in plaque-laden transgenic-
mouse brains, is destined, however inefficiently, to remove Aβ and 
to promote repair implicating the peripheral immune system.
conclusions and pErspEctivEs of anti-
inflammatory trEatmEnt in alzhEimEr’s disEasE
Surveillance, coordinated recruitment of immune cells, removal of 
damaging elements, and tissue repair, that is, the set of sequential 
reactions known as “inflammation”, are functions of the innate 
immune system in the brain, as elsewhere. We postulate that a defec-
tive rather than an excessive inflammatory response contributes to 
AD pathogenesis. Our view has three core ideas (Figure 1):
(i) One is that ApoEε4 plays a key role in early disease pathogenesis 
by damaging astrocytes, the principal holders of the lipopro-
tein. Consequences of astrocyte dysfunction would be: (a) Aβ 
Surprisingly, despite this evidence, ApoEε4 has not been at the 
center stage of AD therapeutics. The principal cells that secrete ApoE 
in the brain are astrocytes and, to a lesser extent, microglia. A recent 
structural analysis of ApoE isoforms has revealed that domain inter-
action and protein misfolding – caused by a difference in a single 
amino acid – distinguish ApoEε4 from ApoEε3 and ApoEε2 (Zhong 
et al., 2009). The introduction of an ApoEε4-like domain interaction 
in mice results in endoplasmic reticulum (ER) stress in astrocytes, 
associated to severe cognitive deficits (Zhong et al., 2009). This indi-
cates that astrocyte dysfunction affecting neurovascular coupling, 
synaptic plasticity, metabolic homeostasis – all phenomena con-
trolled by astrocytes –, along with impaired clearance of Aβ and 
altered inflammation, may underlie ApoEε4-related damage in AD. 
Conversion of ApoEε4 into ApoEε3 by disrupting the domain inter-
action with small molecules is currently being pursued as a therapeu-
tic approach (Ye et al., 2005). It is tempting to speculate that some 
NSAIDs may act as domain-interaction disruptors, and/or reverse 
early astrocyte alterations associated to ApoEε4 expression.
thE rolE of microglia
The clustering of microglia around plaques in post-mortem AD 
brains (Haga et al., 1989) has contributed to three central tenets 
in the field of neuroinflammation and AD. One is that micro-
glia, challenged by Aβ, release neurotoxic factors like ROS, reac-
tive nitrogen species, and elements of the complement system, as 
well as inflammatory mediators including interleukin-1β (IL-1β), 
monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), 
tumor necrosis factor-α (TNF-α), which engage other cells, includ-
ing astrocytes and vascular cells, in a complex interplay of signal-
ing loops that amplify the inflammatory reaction, and cause great 
damage to neurons. The second tenet is that pathology arises when 
microglia is chronically activated, either due to persistence of the 
inducers, or a failure in the resolution mechanisms. And the third 
tenet is that microglia contributes to removal of Aβ plaques by 
phagocytosis. The terms “classic” and “alternative” have been coined 
to define the pro-inflammatory versus the phagocytic status of 
microglia activation, the latter being associated to production of 
growth factors (De et al., 2003). Careful perusal of the evidence 
offers, however, the following, alternative angles to these tenets.
While a wealth of data from brains from diseased individu-
als and mouse models demonstrates that microglia express pro-
inflammatory mediators, data is scant in support that these cause 
disease; information is also lacking about the dynamic interplay 
of functional microglia phenotypes overtime. The noxious role of 
microglia is largely based on: (i) immunohistochemical correla-
tions (Griffin et al., 1995; Arends et al., 2000; Vehmas et al., 2003); 
and (ii) in vitro findings, cultures being a pathological condition 
because the mechanical stress implicit in the isolation procedure 
renders microglia overly reactive (Streit, 2010). Moreover, cultures 
are prepared from postnatal microglia, which may not recapitulate 
the decline of microglial functions in aging (Sastre and Gentleman, 
2010). Alternatively, mitochondrial alterations and oxidative dam-
age, the early signs of damage in AD, may be directly caused by 
soluble Aβ (Tamagno et al., 2002; Lustbader et al., 2004), and/
or be secondary to vascular, metabolic, and synaptic alterations 
caused by ApoEε4-harboring dysfunctional astrocytes. As to the 
notion that sustained inflammation is detrimental, a recent study 
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